The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus.
about
Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?Ribavirin: Past, present and futureModelling hepatitis C therapy--predicting effects of treatmentA pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infectionReduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug ResistanceExpert opinion on the treatment of patients with chronic hepatitis CCell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirinRibavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingHost-based ribavirin resistance influences hepatitis C virus replication and treatment response.Ribavirin Inhibits Parrot Bornavirus 4 Replication in Cell CultureSynthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the LiverThyroid dysfunction in chinese patients with chronic hepatitis C treated with interferon alpha: incidence, long-term outcome and predictive factors.Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.Investigating the Influence of Ribavirin on Human Respiratory Syncytial Virus RNA Synthesis by Using a High-Resolution Transcriptome Sequencing Approach.New therapeutic opportunities for hepatitis C based on small RNA.Retreatment of chronic hepatitis C in previous non-responders and relapsers.Role of ribavirin in HCV treatment response: now and in the future.Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1.Broad-spectrum antiviral agents.The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis CRibavirin inhibits human parainfluenza virus type 2 replication in vitro.Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers.ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro.Effects of Silymarin, Glycyrrhizin, and Oxymatrine on the Pharmacokinetics of Ribavirin and Its Major Metabolite in Rats.Host-directed Inhibitors of Myxoviruses: Synthesis and in vitro Biochemical Evaluation.Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.Asymmetric synthesis of host-directed inhibitors of myxoviruses.Ribavirin in chronic hepatitis C: past and future.Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals.Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.Modeling HCV kinetics under therapy using PK and PD informationRibavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring
P2860
Q24594939-8D51467C-73FC-4F51-A4A3-1364B0B9DCF5Q26775002-06A2A66F-016D-4C55-829B-807470043835Q26864673-21E6E4A7-6DCE-412A-B6FF-BD78A1C585DBQ27023355-0C2F6DFE-5985-43AA-8B97-EF24BA35B4E3Q27488307-C32BD09A-73D6-4CD7-8D81-F30B9BBDABCAQ27489903-7CEC5C11-CAC8-4729-A32B-1265F19C6732Q28474617-ED94555F-74AC-4F87-BEB0-3FF07F6C6111Q33815550-DA1AD89F-7667-42AE-A0DA-29C2019EBDADQ33899320-56544B6C-C0C5-4C08-A72B-E4AF9AEEFA0EQ35077712-E3EAB531-BBEC-4597-A6EF-45DD91D21B49Q35723942-71FCEF56-7665-4862-9F24-D66901DF523CQ35909043-DF18992E-9D19-4A6D-8619-CE254ED40A96Q36329350-0486DB28-813A-4F43-8926-5136D95A9AD4Q36827155-EBA3EFB0-44C0-4B2B-8176-8B725736C636Q36878963-16371430-DEBB-4258-9E9D-984B1339D1B9Q36921336-2E6BACBC-1914-4513-BA44-9A25FCA7EAF6Q36968144-3C1C86FE-78D7-4E47-9E47-EE3CF89D47A8Q37693948-DDF25D79-0B77-4038-9F95-5E8D2A35250BQ38136078-B4DF44DE-1848-4CEF-A52A-16E82B4AB291Q38262107-903617E1-E06A-4BCA-8167-0205D6DCA562Q38519881-A236A154-C648-4E69-A750-40D29AAABA6CQ38915259-A032ACC3-2DC3-4224-BA6B-8898F11D2288Q38963104-6EC67A42-E790-41EE-B5EB-82A2BB1E36EDQ39258088-DFE1F9D8-3FAF-444E-9C6C-79A346E95B04Q39414574-E9B49F62-1943-49B8-8FA2-982E36A4F829Q39434360-2672B1C8-4BD4-41B1-B6C0-3776407EA783Q39869989-71688B4D-4381-4165-8E16-3F22A118BD20Q40821539-80E6F624-B119-4E81-8CAD-3F1DDE3934A7Q40928428-30C83EEA-6E83-4F58-A23D-4D8D4E4D2897Q41144825-7839653F-5564-4F8B-8675-F2C66CEE572FQ41874751-85F4A43A-1E69-4C75-BC24-0A87643D50C1Q42986680-38A71B74-9FEC-4837-94B6-23A4A09AF29CQ43047106-2B83BD5A-593E-4919-960A-425351629502Q47141239-8F707995-C39E-4058-92E4-38255C2B8B1BQ50568686-C5657BA2-A33E-428D-9996-99DA154C5499Q56935271-E3EFB055-5C4F-407F-9C29-C3B042F72401Q59049605-5E3D1300-C013-4CFD-ADE7-2CFB83754E52
P2860
The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The metabolism, pharmacokineti ...... rin against hepatitis C virus.
@ast
The metabolism, pharmacokineti ...... rin against hepatitis C virus.
@en
type
label
The metabolism, pharmacokineti ...... rin against hepatitis C virus.
@ast
The metabolism, pharmacokineti ...... rin against hepatitis C virus.
@en
prefLabel
The metabolism, pharmacokineti ...... rin against hepatitis C virus.
@ast
The metabolism, pharmacokineti ...... rin against hepatitis C virus.
@en
P1476
The metabolism, pharmacokineti ...... rin against hepatitis C virus.
@en
P2093
P2888
P304
P356
10.1007/S00018-005-5455-Y
P577
2006-04-01T00:00:00Z